Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12014-015-9081-x
Title: A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers
Authors: Mahboob, S
Ahn, S.B
Cheruku, H.R
Cantor, D
Rennel, E
Fredriksson, S
Edfeldt, G
Breen, E.J
Khan, A
Mohamedali, A
Muktadir, M.G
Ranganathan, S
Tan, S.-H 
Nice, E
Baker, M.S
Keywords: amphiregulin
carcinoembryonic antigen
caspase 3
CD30 antigen
CD40 antigen
CD69 antigen
CXCL11 chemokine
epidermal growth factor
epithelial derived neutrophil activating factor 78
gamma interferon
granulocyte colony stimulating factor
granulocyte macrophage colony stimulating factor
growth differentiation factor 15
interleukin 1 receptor blocking agent
interleukin 12
interleukin 2
interleukin 4
interleukin 6
interleukin 7
interleukin 8
interleukin 9
macrophage inflammatory protein 1
macrophage inflammatory protein 1alpha
macrophage inflammatory protein 1beta
monocyte chemotactic protein 1
platelet derived growth factor BB
prolactin
tumor necrosis factor
vasculotropin A
adult
aged
Article
bead based multiplex immunoassay
cancer growth
cancer staging
colorectal cancer
controlled study
female
human
immunoassay
immunology test kit
intermethod comparison
limit of detection
major clinical study
male
priority journal
protein blood level
protein expression
proteomics
proximity extension assay
quantitative analysis
Issue Date: 2015
Citation: Mahboob, S, Ahn, S.B, Cheruku, H.R, Cantor, D, Rennel, E, Fredriksson, S, Edfeldt, G, Breen, E.J, Khan, A, Mohamedali, A, Muktadir, M.G, Ranganathan, S, Tan, S.-H, Nice, E, Baker, M.S (2015). A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers. Clinical Proteomics 12 (1) : 10. ScholarBank@NUS Repository. https://doi.org/10.1186/s12014-015-9081-x
Rights: Attribution 4.0 International
Abstract: Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 ?L) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay. Results: Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage. Conclusions: CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes' A + B) and malignant (Dukes' C + D) stages. © 2015 Mahboob et al.
Source Title: Clinical Proteomics
URI: https://scholarbank.nus.edu.sg/handle/10635/183464
ISSN: 15426416
DOI: 10.1186/s12014-015-9081-x
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12014-015-9081-x.pdf1.45 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

28
checked on May 13, 2022

Page view(s)

123
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons